Last:
Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

BrainStorm Cell Therapeutics Inc. is developing a platform technology based on autologous mesenchymal stem cells that have been induced to secrete a variety of neurotrophic factors. The company is in a Phase 2 trial in ALS after having seen excellent safety and efficacy in earlier clinical studies.